文献速递白血病MDS 与骨髓增殖性肿瘤

低甲基化药物联合免疫检查点抑制剂治疗急性髓系白血病和骨髓增生异常综合征

Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
PubMed 文献 · Leukemia · 2018-02-22

免疫检查点抑制剂单药治疗急性髓系白血病(AML)和骨髓增生异常综合征(MDS)的临床疗效有限。低甲基化药物(HMA)如阿扎胞苷在增强抗肿瘤免疫应答的同时,会上调抑制性免疫检查点分子的表达从而抑制免疫应答,这可能是阿扎胞苷耐药的重要机制。这些发现促成了多项HMA联合免疫检查点阻断的临床试验,试验数据显示出令人鼓舞的缓解率和持久缓解,且无需依赖干细胞移植。本综述讨论了支持联合用药的临床前数据,并重点介绍了多项临床试验中HMA联合免疫检查点抑制剂治疗AML/MDS的临床和相关性数据。

要点

  • 免疫检查点抑制剂单药治疗AML/MDS的临床疗效有限。
  • HMA如阿扎胞苷上调抑制性免疫检查点分子表达,可能是阿扎胞苷耐药的机制。
  • HMA联合免疫检查点阻断的临床试验显示出令人鼓舞的缓解率和持久缓解,无需依赖干细胞移植。

核心结论

  • HMA联合免疫检查点抑制剂在AML/MDS中显示出令人鼓舞的缓解率和持久缓解,且无需依赖干细胞移植;临床前数据支持这种联合策略。

研究设计与样本

  • 综述:讨论支持HMA与免疫检查点抑制剂联合使用的临床前数据,并聚焦于多项探究HMA-免疫检查点抑制剂联合治疗AML/MDS的临床试验中出现的临床和相关性数据。

主要发现

  • 免疫检查点抑制剂单药治疗AML/MDS的临床疗效有限。
  • HMA如阿扎胞苷在增强抗肿瘤免疫应答的同时,通过上调抑制性免疫检查点分子的表达来抑制免疫应答。
  • 免疫检查点分子上调可能是阿扎胞苷耐药的重要机制。
  • HMA联合免疫检查点阻断的临床试验数据显示出令人鼓舞的缓解率和持久缓解,且无需依赖干细胞移植。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint inhibitors, as single-agent therapy, have shown modest clinical efficacy in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). As has been successfully shown in other less immunogenic hematologic malignancies, rationally designed combination approaches may be more effective than single-agent checkpoint inhibitors, and may be the approach to pursue in AML/MDS. Hypomethylating agents (HMAs) such as azacitidine, while enhancing anti-tumor immune response, concurrently dampen immune response by upregulating inhibitory immune checkpoint molecule expression. Immune checkpoint molecule upregulation may be an important mechanism of azacitidine resistance. These findings have resulted in multiple clinical trials combining HMAs with immune checkpoint blockade. Clinical trial data have shown encouraging response rates and durable responses without resorting to stem cell transplant. In this review, we discuss preclinical data supporting the use of these agents in combination, and focus on clinical and correlative data emerging from numerous clinical trials investigating HMA-immune checkpoint inhibitor combinations in AML/MDS.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Daver N, Boddu P, Garcia-Manero G, et al. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia. 2018. PMID: 29487386. doi:10.1038/s41375-018-0070-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。